– Clinical data show continued survival benefit, tumor response, and multi-year persistence of Sleeping Beauty-modified CD19-specific CAR+ T cells ––...
Ziopharm
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced the presentation...